share_log

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?

爲什麼癌症專注的Aadi生物科技股票在星期五交易更高?
Benzinga ·  12/20 21:43

On Thursday, Aadi Bioscience, Inc. (NASDAQ:AADI) entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd.

週四,Aadi Bioscience, Inc.(納斯達克股票代碼:AADI)簽訂了獨家許可協議,與藥明生物製劑和杭州達克生物技術有限公司合作,開發和全球商業化臨牀前抗體藥物偶聯物(ADC)的三項資產組合。

Per the terms of the license agreement, Aadi is granted exclusive rights to certain patents and know-how pertaining to three preclinical ADC programs leveraging Hangzhou DAC's CPT113 linker payload technology.

根據許可協議的條款,Aadi被授予與利用杭州DAC CPT113 鏈接器有效載荷技術的三個臨牀前ADC項目相關的某些專利和專有技術的專有權利。

Also Read: Cancer Player Aadi Bioscience Downgraded: Analyst Highlights 'Worse Than Expected' Response Rates.

另請閱讀:癌症公司Aadi Bioscience下調了評級:分析師強調回應率 「低於預期」。

Aadi will pay aggregate upfront payments of $44 million for in-licensing such ADC programs.

Aadi將爲此類ADC計劃的許可支付總額爲4400萬美元的預付款。

Additionally, Aadi will pay cumulative development milestone payments of up to $265 million, cumulative commercial milestone payments of up to $540 million, and single-digit sales royalties.

此外,Aadi將支付高達2.65億美元的累計開發里程碑付款、高達5.4億美元的累計商業里程碑款項以及個位數的銷售特許權使用費。

To support this transaction, Aadi entered into a subscription agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity financing of approximately $100 million.

爲了支持這筆交易,Aadi與某些合格的機構買家和合格投資者簽訂了認購協議,對約1億美元的公共股權融資進行私人投資。

The company is selling 21.59 million shares at $2.40 per share.

該公司將以每股2.40美元的價格出售2159萬股股票。

In August, Aadi Bioscience announced it would halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations.

8月,Aadi Bioscience宣佈將停止計劃在含有TSC1或TSC2失活變異的實體瘤患者中對nab-sirolimus進行註冊的 PRECISION1 試驗。

An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study.

獨立數據監測委員會的一項分析表明,該研究不太可能超過支持加速批准所需的療效閾值,這是這項2期研究的關鍵目標。

Price Action: AADI stock is up 24.1% at $2.87 during the premarket session at last check Friday.

價格走勢:週五最後一次盤前交易中,AADI股價上漲24.1%,至2.87美元。

  • FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
  • 美國食品藥品管理局批准愛奧尼斯製藥公司的罕見遺傳病療法以降低血液中脂肪含量
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論